Drug Trial Radar · NCT04281992
Treatment of Diabetic Foot Ulcers With AUP1602-C
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 28, 2020
Primary completion
Mar 20, 2023
Study completion Mar 20, 2023
Sponsor
- Lead sponsor
- Aurealis OyIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.
Conditions
- Diabetic Foot Ulcer
Interventions
AUP1602-CBiological
AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and potential dose-limiting toxicities (DLTs)Time frame: 4 weeks
- Incidence of Treatment-Emergent Adverse EventsTime frame: 6 months
- Incidence of Wound ClosureTime frame: 6 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Medizinische Hochschule Hannover (MHH) CRC Core Facility
Hanover, Germany
Mikomed
Lodz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.